Article Figures & Data
Figures
- Fig. 1.
Morphology of cells isolated from the ascites fluid of patients with ovarian cystadenocarcinoma (A to F) or with Brenner tumor (G) and grown in cell culture for 2 to 60 days. Phase-contrast microscopy, magnification, ×816. (A) Day 2. A heterogeneous population of cells isolated from ascites fluid (ASC I) contains several cytotoxic lymphocytes and macrophages (small shiny cells), long cells with the morphology of fibroblasts (in the center), and some cells with the morphology of cancer cells (top right). (B) Day 6. In the center of the colony of cancer cells (ASC I), a small syncytium with two nuclei is visible. (C) Day 14. A large syncytium with eight nuclei (ASC I) (right) is in the process of fusion with two enlarged, mononuclear cells containing single nuclei. Granular tubules “budding” from the cells are visible. (D and E) Day 30. Giant syncytia are highly vacuolated and contain several granular, worm-like tubules which are shed by the cells. (D) ASC II. (E) ASC III. (F) Day 60. Apoptosis of the nuclei and cell lysis (ASC III).
- Fig. 2.
Western blotting of antigens p120, p42, and p25 with the anti-HIV-1 gp120 MAb. Lanes: 1 to 3, ASC from different patients after 4 weeks marked by Roman numbers I, II, and V, respectively; 4, ASC VI after 2 weeks in cell culture; 5 to 8, ascites fluid directly obtained from the same patients; 9, solid ovarian cancer from the donor of ASC VI. Mrs are shown to the left (thousands).
- Fig. 3.
Indirect immunofluorescence staining of ASC cells and syncytia (A to C) with MAb RAK-BrI (A and B) or with the anti-HIV-1 gp120 MAb (C). Staining at 2 (A), 4 (B), and 5 (C) weeks is shown. Magnification (A to C), ×2,600.
- Fig. 4.
Effect of anti-HIV-1 MAb 5023 (20 μg/ml) on growth of ASC V cells. Control cells were grown in the absence of MAb 5023 (A), but in the presence of control MAb C63.3 (B).
- Fig. 5.
PCR amplification of ovarian cancer cell DNA with primers SK68 and SK69 derived from HIV-1 gp120. Lanes: 1 to 3, DNA isolated from ASC cells; 4, DNA from ovarian cancer; 5, DNA from normal ovary; 6, DNA from HIV-1-infected cells; 7, ladder marker (125 bp).
- Fig. 6.
Sequences, amplified with HIV-1 gp41-derived primers SK68 and SK69 in ovarian cancer DNA and ASC DNA from two different patients. (A) The sequences identical to that of HIV-1 IIIb are marked by stars. The positions of primers are marked by dashed lines. (B) Amino acid sequence encoded by the HIV-1-like sequences.
- Fig. 7.
Negative staining of the viral particles isolated from the culture media of ASC cells (4 weeks of cell growth in vitro) (A to C) and the ovarian cancer cell line (D and E). Bar, 100 nm. (A, C, and E) Magnification, ×60,000. (B and D) Magnification, ×100,000.
- Fig. 8.
Thin-section electron micrograph of ASC III cells grown for 4 weeks in vitro. Viral particles with a dense center surrounded by a translucent core and covered with a denser shell with spindles are visible. The hexagonal symmetry of the viral particles is visible. The arrows in panel B point to the representative viral particles which best exhibit the structure of the virus. C, cytoplasm; N, nucleus. Bar, 100 nm. (A) Magnification, ×25,550. (B) Magnification, ×71,000.
- Fig. 9.
Thin-section electron micrograph of ASC syncytium after 4 weeks of cell culture. Arrows point to the nuclear invagination of the cytoplasm, where the viral particles are assembled. (A) Cytopathic effects, including nucleus fragmentation and vacuolization. C, cytoplasm; N, nucleus. (B) Magnified fragment of the cytoplasm with viral particles budding from plasma membrane. (C) Viral particles budding from plasma membrane (arrows) and budding into a large vacuole (in the middle). (A) Magnification, ×5,200. (B) Magnification, ×64,000. (C) Magnification, ×48,750.
- Fig. 10.
Morphological transformation of normal breast cells by ASC cell growth medium. Results are shown for cells grown in the absence (A and C) or in the presence (B and D) of ASC medium. (A and B) Phase-contrast microscopy. Magnification, ×816. (C and D) Indirect fluorescence staining with anti-HIV-1 MAb. Magnification, ×2,720.
Tables
